Loading organizations...
§ Private Profile · San Francisco, CA, USA
Biotechnology startup developing non-invasive liquid biopsy tests for early detection of chronic liver diseases like MASH.
Hepta Bio, based in San Francisco, California, develops non-invasive liquid biopsy tests utilizing cell-free DNA epigenetic analysis and AI to enable early detection of chronic diseases such as MASH. Their platform decodes liver biology, including inflammation and fibrosis, from a standard blood draw, aiming to identify patients earlier and guide treatment without invasive biopsies. This technology is designed for population-scale use, addressing conditions like MASH, which affects over 20 million Americans and often goes undiagnosed. The company emerged from stealth in 2023, having secured $6.7 million in seed funding from investors including Felicis Ventures, Illumina Ventures, and SeaX Ventures. Key leadership includes Chief Medical & Scientific Advisor Rohit Loomba. Hepta Bio was founded in 2021 by Hamed Amini, formerly of Grail and Illumina, and Soheil Damangir, previously with Google.
Hepta has raised $6.7M across 1 funding round.
Hepta has raised $6.7M in total across 1 funding round.
Hepta has raised $6.7M in total across 1 funding round.
Hepta's investors include Aydin Senkut, Illumina Ventures, Alumni Ventures, AME Cloud Ventures, SeaX Ventures.
Hepta has raised $6.7M across 1 funding round. Most recently, it raised $6.7M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 5, 2025 | $6.7M Seed | Aydin Senkut, Illumina Ventures | Alumni Ventures, AME Cloud Ventures, SeaX Ventures | Announced |